[S-18-1] アルツハイマー病の前臨床期バイオマーカー

中村昭範 (国立長寿医療研究センター脳機能画像診断開発部)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-2] 前駆期パーキンソン病の病態

西川典子 (国立精神・神経医療研究センター神経内科)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-3] 運動ニューロン疾患の発症前病態とバイオマーカー

勝野雅央 (名古屋大学大学院医学系研究科神経内科学)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-4] RISCA: preclinical cohort of spinocerebellar ataxia

Jen Jen Su (Department of Neurology, University of Bonn)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.